Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 18, 2026.

Truncated and modified amyloid-beta species

Markus P Kummer, Michael T Heneka

Alzheimer's Research & Therapy · 2014 · Review · CC BY

doi:10.1186/alzrt258

Abstract

Alzheimer’s disease pathology is closely connected to the processing of the amyloid precursor protein (APP) resulting in the formation of a variety of amyloid-beta (Aβ) peptides. They are found as insoluble aggregates in senile plaques, the histopathological hallmark of the disease. These peptides are also found in soluble, mostly monomeric and dimeric, forms in the interstitial and cerebrospinal fluid. Due to the combination of several enzymatic activities during APP processing, Aβ peptides exist in multiple isoforms possessing different N-termini and C-termini. These peptides include, to a certain extent, part of the juxtamembrane and transmembrane domain of APP. Besides differences in size, post-translational modifications of Aβ – including oxidation, phosphorylation, nitration, racemization, isomerization, pyroglutamylation, and glycosylation – generate a plethora of peptides with different physiological and pathological properties that may modulate disease progression.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Since its identification from senile plaques, amyloid-beta (Aβ) peptide has been considered to play a central role in the pathology of Alzheimer’s disease (AD). Aβ is thought to accumulate in AD cases because of an imbalance in the production and clearance of this peptide resulting in the formation of the characteristic amyloid plaques in specific brain regions. The large majority of AD cases are of sporadic nature, showing inefficient removal of Aβ, whereas a minority of cases is caused by genetic mutations (familial AD) with an onset typically below age 65 years. Most of these cases are caused by autosomal dominant mutations in genes related to the processing of amyloid precursor protein (APP) leading to increased production of Aβ.

To generate Aβ from APP, the precursor has to be cleaved by a set of two proteases (Figure 1). The first cleavage occurs at a luminal, juxtamembrane position, resulting in the formation of a membrane-bound C-terminal stub that, in a subsequent step, is cleaved by an unconventional protease complex, called γ-secretase, within the transmembrane domain, thereby liberating Aβ. Both cleavages have been shown to be imprecise. β-site amyloid precursor protein cleaving enzyme 1 (BACE1), the enzyme that conducts the initial processing, step-cleaves APP at a minimum of two positions, whereas γ-secretase generates a variety of different Aβs spanning 34 to 50 amino acids in length.

Most AD cases are sporadic, however, without changes in the production of the Aβ peptide. The propensity to form aggregates and toxic species may therefore be driven by factors other than changes in the production of certain Aβ peptides. Several post-translational modifications (PTMs) have been discovered that on the whole increase the aggregation rate of Aβ (Figure 2). Some of these modifications, such as oxidation and nitration, are obviously induced by the inflammatory milieu that is a component of AD.

PTMs can function as a molecular switch to evoke cellular responses, but one should consider that they may also be a result of protein aging that is random and without any physiological impact.

Amyloid-beta species generated by α-secretase, β-secretase, and γ-secretase

Three enzymatic activities are involved in APP processing, and were named α-secretase, β-secretase, and γ-secretase at a time when their molecular identities were unknown. APP exists in several isoforms ranging from 695 to 770 amino acids in length, including the domain from which the Aβ peptide derives. In APP695 (the most abundant isoform in the brain) this domain ranges from amino acids 597 to 638. In an initial step, APP is cleaved at a juxtamembrane position at the luminal side of the membrane. This cleavage is mediated at different positions by either α-secretase or β-secretase in different compartments of the cell. The majority of APP molecules in non-neuronal cells are initially cleaved by α-secretase between positions 16 and 17 of the Aβ domain. This is the so-called non-amyloidogenic pathway since the cleavage occurs within the Aβ domain, thereby preventing the production of Aβ. This event generates a stub called α-C-terminal fragment as well as a large ectodomain called sAPPα. Several members of the ADAM family of proteases are able to mediate this cleavage, but in neurons this function is likely to be exerted by the constitutively active ADAM10 protease.

In the amyloidogenic pathway, leading to the production of Aβ peptides, β-secretase mediates the initial rate-limiting step. The membrane-bound aspartyl-protease BACE1 has been identified as the responsible enzyme. APP is cleaved by this enzyme before position 1 of the Aβ domain, resulting in the release of a large ectodomain and the formation of a stub called β-C-terminal fragment. In addition, BACE1 can also cleave APP within the Aβ domain between positions 10 and 11 (β′ site). Subsequently, both N-terminally cleaved precursors are further processed by γ-secretase, a complex that consists of at least the proteins APH-1, PEN-2, nicastrin and presenilin 1 or presenilin 2. The transmembrane proteins presenilin 1 and presenilin 2 possess two critical aspartyl residues that are part of the catalytic domain of this γ-secretase subunit. The cleavage occurs within the transmembrane domain of APP, generating C-terminally truncated peptides ending with amino acids 37 to 43, due to an imprecise cleavage of these enzymes. The resulting peptides are liberated into extracellular fluids such as cerebrospinal fluid (CSF), plasma or interstitial fluid. This phenomenon is not fully understood, but endoproteolysis is thought to occur stepwise, cleaving the C-terminal stubs several times within their transmembrane domain. These cleavages are approximately three amino acids apart: one at amino acid 48 or 49, followed by another one at position 45 or 46, and ending with a final cleavage most often at position 38, 40 or 42. At least in the CSF of nondemented controls, about one-half of the Aβ ends at amino acid 40, 16% ends at amino acid 38, and 10% ends at amino acid 42. Aβ species ending with the alanine at position 42 have a stronger tendency to aggregate as compared with Aβ1–40. These species are thought to be the driving factor for the formation of amyloid plaques and the neurotoxic effects. During this last step, other minor cleavage sites have been observed at positions 34, 37, 39, and 43. There are even shorter Aβ isoforms (Aβ1–17/18/19/20) that depend on γ-secretase but the precise mechanism of their generation is unknown.

Both processing pathways lead to a large variety of peptides that start either at position 1 or position 11 caused by cleavage by BACE1 or at position 17 mediated by α-secretase. The latter peptides are called p3 but are not found in senile plaques, and neither do they yet appear to have any pathological or physiological role. Most of these N-terminal starting points are found in combination with the heterogeneity caused by the cleavage of γ-secretase.

To make things even more complicated, the amyloidogenic pathway and the nonamyloidogenic pathway seem not to be mutually exclusive. There are shorter isoforms of Aβ (Aβ1–14/15/16) present in the CSF that do not depend on γ-secretase cleavage but are sensitive to inhibitors of α-secretase. Interestingly, Aβ1–14/15/16 increase after γ-secretase treatment in CSF. This leads to the conclusion that C-terminal BACE1-cleaved stubs (C99) are not exclusive substrates for γ-secretase, and that C99 can reach compartments with α-secretase activity resulting in the liberation of Aβ1–14/15/16 along alternative pathways.

N-terminal amyloid-beta truncations independent of α-secretase or β-secretase

There are several N-terminal truncations observed in AD that cannot be explained by the action of the above-described enzymes. In general, N-terminal truncations make up the majority of Aβ species in AD but not in the transgenic mice mouse model, which might explain the differences in the molecular mechanisms of amyloid deposition. In addition, the shortening of the N-terminus increases the propensity of Aβ to form aggregates in vitro. Since Aβ is degraded by several secretory proteases, such as insulin-degrading enzyme and neprilysin among others, it is possible that truncations arise from these enzymes.

The 2-x Aβ species has been found to be increased in the brains of AD patients and decreased in the CSF of AD patients. There was a suggestion that this species might derive from the combined action of BACE1 followed by aminopeptidase A. Recently, the metalloprotease meprin-beta was reported to initially shed APP in a BACE1-independent fashion, releasing different Aβ species with several cleavage sites. These sites are reported to be identical with or proximal to the known β-secretase cleavage site, and overexpression of meprin-beta generates Aβ2–40. However, further studies and appropriate mouse models are necessary to investigate the contribution of meprin-beta in AD.

The 3-x Aβ species has been detected in a mouse model of AD and in senile plaques from brains of late AD cases. It has been suggested that this species is generated by Cu2+-mediated amide hydrolysis or the peptide bond between amino acids 2 and 3 of Aβ.

One of the first Aβ peptides reported was the N-terminal truncated 4-x species. In comparison with other species, Aβ4–42 was found to be relatively abundant in AD and vascular dementia. In vivo, mice overexpressing Aβ4–42 suffer from a massive CA1 pyramidal neuronal loss, accompanied by memory dysfunction. There is so far no candidate enzyme that mediates this cleavage.

The 5-x Aβ species was initially described in cells expressing an APP lacking the C-terminal 31 amino acids, but has also been discovered in AD patients using a 5-x Aβ neo-epitope antibody and in nondemented controls by mass spectometry. Interestingly, using APP-overexpressing cell lines, inhibition of BACE1 resulted in the appearance of Aβ5–40. This species has also been detected in the 5XFAD mouse model of AD and in the CSF of dogs treated with BACE1 inhibitor.

The largest amino truncations, aside from that at position 11 mediated by BACE1, are so far the cleavages that occur before amino acids 7, 8 and 9 observed in the brains of AD patients. A candidate enzyme for the formation of the 8-x Aβ species might be angiotensin-converting enzyme, but so far there are no in vivo data supporting this pathway.

Oxidation

The most prominent site of oxidative changes within Aβ is the methionine at position 35 (Met35). Increased oxidative stress has been described in the brains of mild cognitive impaired and AD patients. Part of this oxidative stress is mediated by the Aβ peptide itself, but other mechanisms, such as inflammatory inducers and others, may also be relevant.

Oxidation of Met35 to methionine sulfoxide in AD was first observed years ago. The reaction proceeds through a radical intermediate that can be prevented by the use of radical scavengers. Several studies demonstrated that oxidation of Met35 impedes the formation of Aβ protofibrils and fibrils from monomers. A role for Met35-oxidized Aβ in the formation of ion-channel-like structures in lipid membranes has also been reported.

Phosphorylation

In theory, Aβ possesses three potential phosphorylation sites at serine residues 8 and 26 and at tyrosine residue 10. There are numerous examples of phosphorylated extracellular/luminal protein suggesting the existence of extracellular kinases that facilitate this PTM. Phosphorylation of the serine at position 26 has been described in NT2 neurons and AD brains. In vitro, this PTM is generated by the action of the cdc2 kinase. In turn, using a cdc2 kinase inhibitor, the neurotoxic effect of Aβ on NT-2 neurons can be reduced.

Phosphorylation of Aβ at serine 8 has been studied in more detail. Using phospho-serine-8-specific Aβ antibodies revealed the presence of phosphorylated Aβ in AD mouse models and AD. Under pathological conditions this species was found to be localized to amyloid plaques, but could also be found intracellularly. Biophysically, this PTM increases the formation of oligomeric Aβ aggregates that represent nuclei for fibrillization. This species shows increased toxicity in drosophila models as compared with nonphosphorylated Aβ. In addition, serine 8-phosphorylated Aβ is resistant to degradation by insulin degrading enzyme.

Nitric-oxide-caused modifications

Nitric oxide (NO) induces several PTMs, including the formation of S-nitrothiols at cysteine residues and nitration and dityrosine formation at tyrosine residues. Increased presence of these NO-caused PTMs has been observed in AD. The source of NO during AD is most probably the enzyme NOS2, which is upregulated in AD. As a molecular target, tyrosine 10 of Aβ has been shown to increase the propensity of Aβ to aggregate and has been identified in the core of the amyloid plaques. The reaction of Aβ with peroxynitrite, an intermediate NO product, in vitro has been shown to generate both nitrated Aβ and dityrosine-coupled Aβ. The latter modification could also be detected in the core of amyloid plaques and may stabilize Aβ dimers. Nitrated Aβ was able to initiate plaque formation in APP/PS1 mice, suggesting a central role during the early phase of AD. Hippocampal long-term potentiation was suppressed more by nitrated Aβ compared with non-nitrated Aβ. This demonstrates that this PTM is involved in both the functional and structural changes in AD. In addition, formation of this Aβ species is favored by oxidative stress.

Glycosylations

Mass spectrometry analysis of controls and AD patients revealed the presence of O-glycosylated Aβ species in CSF. The glycoforms included monosialylated, disialylated, and trisialylated modifications, as well as lactone modifications. The exact molecular nature of the glycosylation has not been determined and could therefore be GlcNAc, GalNAc, or ManNAc in either α-linkage or β-linkage to the conjugated amino acid. Glycosylation occurred on Aβ1–15/16/17/18/19/20, Aβ3–15, Aβ4–15, Aβ4–17, and Aβ5–17 peptides, with Aβ1–15 and Aβ1–17 peptides being the most abundant of all Aβ1–X glycopeptides. The absolute concentration for glycosylated Aβ1–15 was calculated to be 10 to 30 pg/ml CSF, whereas that for unglycosylated Aβ1–15 ranged from 100 to 200 pg/ml. For Aβ1–15 and Aβ1–17 the glycosylations were selectively attached to tyrosine 10 of the Aβ sequence. The lack of glycosylated Aβ1-40/42 peptides in CSF led to the conclusion that tyrosine 10 O-glycosylation in APP modifies the γ-secretase cleavage, because of the proximity of this glycosylation to the transmembrane domain.

Pyroglutamylation

The initial attempts to identity the N-terminus of Aβ revealed a minor species beginning with glutamic acid at position 3. Development of specific antibodies to pyroglutamate Aβ demonstrated its weak solubility and presence in amyloid plaques. As an initial step, formation of pyroglutamate-modified Aβ at position 3 (3pE-Aβ) requires the removal of the first two amino acids from Aβ. Aminopeptidase A has been suggested as an enzyme facilitating this processing, but this has yet to be proven. In addition, spontaneous amide hydrolysis by Cu2+ has been reported. Further, another pyroglutamate modification at aspartate 11 was discovered (11pE-Aβ). This species may arise from the alternative BACE1 cleavage side in APP. In a subsequent step, the terminal glutamate is converted to a pyroglutamate in a dehydration reaction. This reaction can be catalyzed by the enzyme glutaminyl cyclase, which is increased in AD. Reduction of glutaminyl cyclase results in reduced formation of pyroglutamate Aβ in vitro and in vivo. Further, reduced glutaminyl cyclase expression in AD mouse models is accompanied by reductions in Aβ40/42 levels, reduced plaque burden, inflammatory reaction, and improved memory and spatial learning.

In vitro, 3pE-Aβ42 has a similar toxicological profile on neuronal cells to that of Aβ1–42, which was confirmed by intracerebroventricular injections of either 3pE-Aβ42 or Aβ1–42. Like many changes in the N-terminus of Aβ, 3pE-Aβ and 11pE-Aβ show increased propensity to aggregate and to form β-sheets in vitro. This may be caused by higher hydrophobicity since two charges are lost during conversion. pE-Aβ has been detected in a variety of AD mouse models, yet the time of first appearance during pathology varies strongly between different mouse models – ranging from 2 months in the APP/PS1KI model, to 16 months in the Tg2576 model, to 15 months in the APP23 model. Interestingly, there has been extensive neurotoxicity described in mouse models that generate pyroglutamate-modified Aβ.

Isomerization

Peptides are susceptible to spontaneous, non-enzymatic isomerization particularly at asparagine and aspartate residues, resulting in the formation of isoaspartate. These aspartyl-bond isomerizations affect the secondary structure of the peptide and may therefore be critical for the development of pathological processes such as aggregation and deposition. In parenchymal plaque core preparations, the predominant species of Aβ at the aspartyl residues 1 and 7 is the l-isoaspartyl form. Interestingly, the amount of isoaspartyl residues in Aβ preparations from vascular depositions is lower compared with preparations from senile plaques, suggesting that Aβ from plaques are older since this PTM increases over the lifetime. Isomerization of aspartate 23 has not so far been detected by biochemical means in AD brains.

In vitro, substitutions of positions 1, 7 and 23 of Aβ by isoaspartate increased the tendency of these peptides to form β-pleated sheets, to form aggregates and to contribute to the enhanced insolubility and resistance to enzymatic degradation. The presence of isoaspartate-7 Aβ detected by specific antibodies was suggested to be an indicator of plaque age since this was found mostly in the core of amyloid plaques and correlated with dementia severity.

Racemization

Racemization is the process of conversion of enantiomers so that both enantiomers are present. In the case of amino acids this is the conversion from the l-form to the d-form, especially at seryl and aspartyl residues. Presence of d-enantiomers of aspartyl and seryl residues in Aβ have long been described. As for isomerized Aβ, the presence of racemized aspartyl residues in Aβ was found to be higher in amyloid plaques compared with vascular Aβ. In vitro, racemization of Aβ can be induced by radicals. In a recent study, the enrichment of d-Asp1 as well as of its isomer d-isoAsp1 could be demonstrated in the tissue of AD patients by mass spectometry. d-Ser26-Aβ1–40 possesses a stronger tendency to form fibrils.

Use of amyloid-beta species as diagnostic marker and as a target for treatment

Because of its disease-dependent regulation in the CSF, Aβ has been used as a biomarker for AD. In particular, the concentration of Aβ1–42 in the CSF undergoes a characteristic drop during disease progression, which is interpreted as the consequence of the ongoing parenchymal Aβ deposition in senile plaques. In addition, the CSF levels of Aβ1–40 remain constant so that the ratio of Aβ1–42/Aβ1–40 is a valuable predictor. Since the C-terminal truncated Aβ1–14/15 species are elevated after inhibition of γ-secretase, their use as a readout for trials aiming at the modulation of γ-secretase has been suggested. The sensitivity can be increased by combining the markers Aβ1–42, Aβ1–38 and pTau, resulting in a 94% discrimination between nondemented patients and AD patients. Beyond the diagnosis of AD, the concentration of Aβ1–38 is specifically lowered in the CSF of patients affected by fronto-temperal dementia.

The search for human auto-antibodies in plasma and CSF revealed that most antibodies recognized either oligomeric or post-translationally modified Aβ, suggesting that this species might be a relevant target for passive or active immunotherapy. Since it is unknown whether unmodified Aβ has a physiological role, there is a certain risk that preventive immunotherapy may cause undesirable effects. In addition, decreased levels of Aβ autoantibodies might even contribute to disease progression as has been shown for pyroglutamate-modified Aβ. The immunotherapy directed at pathological Aβ species is therefore a road that should be followed.

Several PTMs of Aβ increase the tendency of Aβ to aggregate and are found in the core of amyloid plaques, suggesting that plaque formation depends on them. The use of inhibitors that interfere with their formation therefore has to be evaluated. In particular, inhibitors for glutaminyl cyclase, the relevant kinases for the phosphorylation of Aβ and NO-producing enzymes, especially NOS2, should be tested as a therapeutic option.

Conclusion

From the plethora of Aβ species, some are generated very early during APP processing, some are modified immediately afterwards, or others are found or generated in certain cellular or extracellular compartments, and some are actually markers for the slow to non-existent turnover of these peptides in amyloid plaques. Certain regions of Aβ obviously contribute differentially to its properties, like N-terminal truncations, and certain amino acids are hotspots for PTMs. There is a possibility that some of these species might serve as excellent diagnostic markers or therapeutic targets in the future.

Abbreviations

AD: Alzheimer’s disease; APP: Amyloid precursor protein; Aβ: Amyloid-beta; BACE1: β-site amyloid precursor protein cleaving enzyme 1; CSF: Cerebrospinal fluid; Met35: Methionine at position 35; NO: Nitric oxide; PTM: Post-translational modification.

Competing interests

The authors declare that they applied for a patent for the use of nitrated Aβ.

Authors’ contributions

MPK and MTH wrote the manuscript. Both authors read and approved the final manuscript.

References 93

  1. 1.

    Querfurth HW LaFerla FM Alzheimer’s diseaseN Engl J Med2010 6329344

    Not in our library10.1056/nejmra0909142

  2. 2.

    Mawuenyega KG Sigurdson W Ovod V Munsell L Kasten T Morris JC Yarasheski KE Bateman RJ Decreased clearance of CNS β-amyloid in Alzheimer’s diseaseScience2010 617741774

    Not in our library10.1126/science.1197623

  3. 3.

    Heneka MT O’Banion MK Terwel D Kummer MP Neuroinflammatory processes in Alzheimer’s diseaseJ Neural Transm Vienna Austria 19962010 6919947

    Not in our library10.1007/s00702-010-0438-z

  4. 4.

    Thinakaran G Koo EH Amyloid precursor protein trafficking, processing, and functionJ Biol Chem2008 62961529619

    Not in our library10.1074/jbc.r800019200

  5. 5.

    Kuhn P-H Wang H Dislich B Colombo A Zeitschel U Ellwart JW Kremmer E Rossner S Lichtenthaler SF ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neuronsEMBO J2010 630203032

    Not in our library10.1038/emboj.2010.167

  6. 6.

    Vassar R Bennett BD Babu-Khan S Kahn S Mendiaz EA Denis P Teplow DB Ross S Amarante P Loeloff R Luo Y Fisher S Fuller J Edenson S Lile J Jarosinski MA Biere AL Curran E Burgess T Louis JC Collins F Treanor J Rogers G Citron M Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACEScience1999 6735741

    Not in our library10.1126/science.286.5440.735

  7. 7.

    Seubert P Vigo-Pelfrey C Esch F Lee M Dovey H Davis D Sinha S Schlossmacher M Whaley J Swindlehurst C Isolation and quantification of soluble Alzheimer’s beta-peptide from biological fluidsNature1992 6325327

    Not in our library10.1038/359325a0

  8. 8.

    Edbauer D Winkler E Regula JT Pesold B Steiner H Haass C Reconstitution of gamma-secretase activityNat Cell Biol2003 6486488

    Not in our library10.1038/ncb960

  9. 9.

    Takami M Nagashima Y Sano Y Ishihara S Morishima-Kawashima M Funamoto S Ihara Y γ-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragmentJ Neurosci Off J Soc Neurosci2009 61304213052

    Not in our library10.1523/jneurosci.2362-09.2009

  10. 10.

    Qi-Takahara Y Morishima-Kawashima M Tanimura Y Dolios G Hirotani N Horikoshi Y Kametani F Maeda M Saido TC Wang R Ihara Y Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretaseJ Neurosci Off J Soc Neurosci2005 6436445

    Not in our library10.1523/jneurosci.1575-04.2005

  11. 11.

    Bibl M Gallus M Welge V Lehmann S Sparbier K Esselmann H Wiltfang J Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptidesProteomics Clin Appl2012 6163169

    Not in our library10.1002/prca.201100082

  12. 12.

    Haass C Selkoe DJ Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptideNat Rev Mol Cell Biol2007 6101112

    Not in our library10.1038/nrm2101

  13. 13.

    Beher D Wrigley JDJ Owens AP Shearman MS Generation of C-terminally truncated amyloid-β peptides is dependent on γ-secretase activityJ Neurochem2002 6563575

    Not in our library10.1046/j.1471-4159.2002.00985.x

  14. 14.

    Portelius E Price E Brinkmalm G Stiteler M Olsson M Persson R Westman-Brinkmalm A Zetterberg H Simon AJ Blennow K A novel pathway for amyloid precursor protein processingNeurobiol Aging2011 610901098

    Not in our library10.1016/j.neurobiolaging.2009.06.002

  15. 15.

    Haass C Hung AY Schlossmacher MG Teplow DB Selkoe DJ β-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanismsJ Biol Chem1993 630213024

    Not in our library

  16. 16.

    Portelius E Van Broeck B Andreasson U Gustavsson MK Mercken M Zetterberg H Borghys H Blennow K Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogsJ Alzheimers Dis2010 610051012

    Not in our library10.3233/jad-2010-100573

  17. 17.

    Portelius E Dean RA Gustavsson MK Andreasson U Zetterberg H Siemers E Blennow K A novel Aβ isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer diseaseAlzheimers Res Ther2010 67

    Not in our library10.1186/alzrt30

  18. 18.

    Jäger S Leuchtenberger S Martin A Czirr E Wesselowski J Dieckmann M Waldron E Korth C Koo EH Heneka M Weggen S Pietrzik CU Alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Aβ generationJ Neurochem2009 613691382

    Not in our library10.1111/j.1471-4159.2009.06420.x

  19. 19.

    Ancolio K Dumanchin C Barelli H Warter JM Brice A Campion D Frébourg T Checler F Unusual phenotypic alteration of beta amyloid precursor protein (βAPP) maturation by a new Val-715 → Met βAPP-770 mutation responsible for probable early-onset Alzheimer’s diseaseProc Natl Acad Sci USA1999 641194124

    Not in our library10.1073/pnas.96.7.4119

  20. 20.

    Schieb H Kratzin H Jahn O Möbius W Rabe S Staufenbiel M Wiltfang J Klafki HW Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloidJ Biol Chem2011 63374733758

    Not in our library10.1074/jbc.m111.246561

  21. 21.

    Sergeant N Bombois S Ghestem A Drobecq H Kostanjevecki V Missiaen C Wattez A David J-P Vanmechelen E Sergheraert C Delacourte A Truncated beta-amyloid peptide species in pre-clinical Alzheimer’s disease as new targets for the vaccination approachJ Neurochem2003 615811591

    Not in our library10.1046/j.1471-4159.2003.01818.x

  22. 22.

    Kalback W Watson MD Kokjohn TA Kuo Y-M Weiss N Luehrs DC Lopez J Brune D Sisodia SS Staufenbiel M Emmerling M Roher AE APP transgenic mice Tg2576 accumulate Aβ peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer’s disease senile plaquesBiochemistry (Mosc)2002 6922928

    Not in our library10.1021/bi015685+

  23. 23.

    Pike CJ Overman MJ Cotman CW Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitroJ Biol Chem1995 62389523898

    Not in our library10.1074/jbc.270.41.23895

  24. 24.
    β ‐Amyloid Degradation and Alzheimer′s Disease · 2006
    No notice
  25. 25.

    Wiltfang J Esselmann H Cupers P Neumann M Kretzschmar H Beyermann M Schleuder D Jahn H Rüther E Kornhuber J Annaert W De Strooper B Saftig P Elevation of beta-amyloid peptide 2–42 in sporadic and familial Alzheimer’s disease and its generation in PS1 knockout cellsJ Biol Chem2001 64264542657

    Not in our library10.1074/jbc.m102790200

  26. 26.

    Arai T Akiyama H Ikeda K Kondo H Mori H Immunohistochemical localization of amyloid beta-protein with amino-terminal aspartate in the cerebral cortex of patients with Alzheimer’s diseaseBrain Res1999 6202206

    Not in our library10.1016/s0006-8993(98)01366-3

  27. 27.

    Bibl M Gallus M Welge V Esselmann H Wolf S Rüther E Wiltfang J Cerebrospinal fluid amyloid-β 2–42 is decreased in Alzheimer’s, but not in frontotemporal dementiaJ Neural Transm Vienna Austria 19962012 6805813

    Not in our library10.1007/s00702-012-0801-3

  28. 28.

    Bien J Jefferson T Causević M Jumpertz T Munter L Multhaup G Weggen S Becker-Pauly C Pietrzik CU The metalloprotease meprin β generates amino terminal-truncated amyloid β peptide speciesJ Biol Chem2012 63330433313

    Not in our library10.1074/jbc.m112.395608

  29. 29.

    Wittnam JL Portelius E Zetterberg H Gustavsson MK Schilling S Koch B Demuth H-U Blennow K Wirths O Bayer TA Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer diseaseJ Biol Chem2012 681548162

    Not in our library10.1074/jbc.m111.308601

  30. 30.

    Casas C Sergeant N Itier J-M Blanchard V Wirths O van der Kolk N Vingtdeux V van de Steeg E Ret G Canton T Drobecq H Clark A Bonici B Delacourte A Benavides J Schmitz C Tremp G Bayer TA Benoit P Pradier L Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic modelAm J Pathol2004 612891300

    Not in our library10.1016/s0002-9440(10)63388-3

  31. 31.

    Güntert A Döbeli H Bohrmann B High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brainNeuroscience2006 6461475

    Not in our library10.1016/j.neuroscience.2006.08.027

  32. 32.

    Drew SC Masters CL Barnham KJ Alanine-2 carbonyl is an oxygen ligand in Cu2+ coordination of Alzheimer’s disease amyloid-beta peptide – relevance to N-terminally truncated formsJ Am Chem Soc2009 687608761

    Not in our library10.1021/ja903669a

  33. 33.

    Masters CL Simms G Weinman NA Multhaup G McDonald BL Beyreuther K Amyloid plaque core protein in Alzheimer disease and Down syndromeProc Natl Acad Sci USA1985 642454249

    Not in our library10.1073/pnas.82.12.4245

  34. 34.

    Lewis H Beher D Cookson N Oakley A Piggott M Morris CM Jaros E Perry R Ince P Kenny RA Ballard CG Shearman MS Kalaria RN Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementiaNeuropathol Appl Neurobiol2006 6103118

    Not in our library10.1111/j.1365-2990.2006.00696.x

  35. 35.
    N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits · 2013
    No notice
  36. 36.

    Takeda K Araki W Akiyama H Tabira T Amino-truncated amyloid beta-peptide (Aβ5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer’s disease brainFASEB J Off Publ Fed Am Soc Exp Biol2004 617551757

    Not in our library10.1096/fj.03-1070fje

  37. 37.

    Murayama KS Kametani F Tabira T Araki W A novel monoclonal antibody specific for the amino-truncated beta-amyloid Aβ5–40/42 produced from caspase-cleaved amyloid precursor proteinJ Neurosci Methods2007 6244249

    Not in our library10.1016/j.jneumeth.2006.11.010

  38. 38.

    Portelius E Olsson M Brinkmalm G Rüetschi U Mattsson N Andreasson U Gobom J Brinkmalm A Hölttä M Blennow K Zetterberg H Mass spectrometric characterization of amyloid-β species in the 7PA2 cell model of Alzheimer’s diseaseJ Alzheimers Dis2013 68593

    Not in our library10.3233/jad-2012-120994

  39. 39.
    BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system. · 2012
    Not checked
  40. 40.

    Hu J Igarashi A Kamata M Nakagawa H Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicityJ Biol Chem2001 64786347868

    Not in our library10.1074/jbc.m104068200

  41. 41.

    Näslund J Schierhorn A Hellman U Lannfelt L Roses AD Tjernberg LO Silberring J Gandy SE Winblad B Greengard P Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal agingProc Natl Acad Sci USA1994 683788382

    Not in our library10.1073/pnas.91.18.8378

  42. 42.

    Hensley K Aksenova M Carney JM Harris M Butterfield DA Amyloid beta-peptide spin trapping. I: peptide enzyme toxicity is related to free radical spin trap reactivityNeuroreport1995 6489492

    Not in our library10.1097/00001756-199502000-00021

  43. 43.

    Palmblad M Westlind-Danielsson A Bergquist J Oxidation of methionine 35 attenuates formation of amyloid beta-peptide 1–40 oligomersJ Biol Chem2002 61950619510

    Not in our library10.1074/jbc.m112218200

  44. 44.

    Hou L Kang I Marchant RE Zagorski MG Methionine 35 oxidation reduces fibril assembly of the amyloid Aβ-(1–42) peptide of Alzheimer’s diseaseJ Biol Chem2002 64017340176

    Not in our library10.1074/jbc.c200338200

  45. 45.

    Barnham KJ Ciccotosto GD Tickler AK Ali FE Smith DG Williamson NA Lam Y-H Carrington D Tew D Kocak G Volitakis I Separovic F Barrow CJ Wade JD Masters CL Cherny RA Curtain CC Bush AI Cappai R Neurotoxic, redox-competent Alzheimer’s beta-amyloid is released from lipid membrane by methionine oxidationJ Biol Chem2003 64295942965

    Not in our library10.1074/jbc.m305494200

  46. 46.

    Milton NG Phosphorylation of amyloid-beta at the serine 26 residue by human cdc2 kinaseNeuroreport2001 638393844

    Not in our library10.1097/00001756-200112040-00047

  47. 47.

    Kumar S Rezaei-Ghaleh N Terwel D Thal DR Richard M Hoch M Mc Donald JM Wüllner U Glebov K Heneka MT Walsh DM Zweckstetter M Walter J Extracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer’s diseaseEMBO J2011 622552265

    Not in our library10.1038/emboj.2011.138

  48. 48.

    Kumar S Wirths O Theil S Gerth J Bayer TA Walter J Early intraneuronal accumulation and increased aggregation of phosphorylated Aβ in a mouse model of Alzheimer’s diseaseActa Neuropathol (Berl)2013 6699709

    Not in our library10.1007/s00401-013-1107-8

  49. 49.

    Kumar S Singh S Hinze D Josten M Sahl H-G Siepmann M Walter J Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymesJ Biol Chem2012 686418651

    Not in our library10.1074/jbc.m111.279133

  50. 50.

    Radi R Cassina A Hodara R Quijano C Castro L Peroxynitrite reactions and formation in mitochondriaFree Radic Biol Med2002 614511464

    Not in our library10.1016/s0891-5849(02)01111-5

  51. 51.

    Butterfield DA Reed TT Perluigi M De Marco C Coccia R Keller JN Markesbery WR Sultana R Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer’s diseaseBrain Res2007 6243248

    Not in our library10.1016/j.brainres.2007.02.084

  52. 52.

    Castegna A Thongboonkerd V Klein JB Lynn B Markesbery WR Butterfield DA Proteomic identification of nitrated proteins in Alzheimer’s disease brainJ Neurochem2003 613941401

    Not in our library10.1046/j.1471-4159.2003.01786.x

  53. 53.

    Heneka MT Wiesinger H Dumitrescu-Ozimek L Riederer P Feinstein DL Klockgether T Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer diseaseJ Neuropathol Exp Neurol2001 6906916

    Not in our library10.1093/jnen/60.9.906

  54. 54.

    Vodovotz Y Lucia MS Flanders KC Chesler L Xie QW Smith TW Weidner J Mumford R Webber R Nathan C Roberts AB Lippa CF Sporn MB Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer’s diseaseJ Exp Med1996 614251433

    Not in our library10.1084/jem.184.4.1425

  55. 55.

    Kummer MP Hermes M Delekarte A Hammerschmidt T Kumar S Terwel D Walter J Pape H-C König S Roeber S Jessen F Klockgether T Korte M Heneka MT Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formationNeuron2011 6833844

    Not in our library10.1016/j.neuron.2011.07.001

  56. 56.
    A central role for dityrosine crosslinking of Amyloid-β in Alzheimer’s disease · 2013
    No notice
  57. 57.

    Thiabaud G Pizzocaro S Garcia-Serres R Latour J-M Monzani E Casella L Heme binding induces dimerization and nitration of truncated β-amyloid peptide Aβ16 under oxidative stressAngew Chem Int Ed Engl2013 680418044

    Not in our library10.1002/anie.201302989

  58. 58.

    Halim A Brinkmalm G Rüetschi U Westman-Brinkmalm A Portelius E Zetterberg H Blennow K Larson G Nilsson J Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluidProc Natl Acad Sci USA2011 61184811853

    Not in our library10.1073/pnas.1102664108

  59. 59.

    Mori H Takio K Ogawara M Selkoe DJ Mass spectrometry of purified amyloid beta protein in Alzheimer’s diseaseJ Biol Chem1992 61708217086

    Not in our library

  60. 60.

    Saido TC Iwatsubo T Mann DM Shimada H Ihara Y Kawashima S Dominant and differential deposition of distinct beta-amyloid peptide species, AβN3(pE), in senile plaquesNeuron1995 6457466

    Not in our library10.1016/0896-6273(95)90301-1

  61. 61.

    Sevalle J Amoyel A Robert P Fournié-Zaluski M-C Roques B Checler F Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptideJ Neurochem2009 6248256

    Not in our library10.1111/j.1471-4159.2009.05950.x

  62. 62.

    Liu K Solano I Mann D Lemere C Mercken M Trojanowski JQ Lee VM-Y Characterization of Aβ11–40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s diseaseActa Neuropathol (Berl)2006 6163174

    Not in our library10.1007/s00401-006-0077-5

  63. 63.

    Huse JT Liu K Pijak DS Carlin D Lee VM-Y Doms RW Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer’s disease brainJ Biol Chem2002 61627816284

    Not in our library10.1074/jbc.m111141200

  64. 64.

    Liu K Doms RW Lee VM-Y Glu11 site cleavage and N-terminally truncated Aβ production upon BACE overexpressionBiochemistry (Mosc)2002 631283136

    Not in our library10.1021/bi015800g

  65. 65.

    Schilling S Hoffmann T Manhart S Hoffmann M Demuth H-U Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditionsFEBS Lett2004 6191196

    Not in our library10.1016/s0014-5793(04)00300-x

  66. 66.

    Schilling S Zeitschel U Hoffmann T Heiser U Francke M Kehlen A Holzer M Hutter-Paier B Prokesch M Windisch M Jagla W Schlenzig D Lindner C Rudolph T Reuter G Cynis H Montag D Demuth H-U Rossner S Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer’s disease-like pathologyNat Med2008 611061111

    Not in our library10.1038/nm.1872

  67. 67.

    Cynis H Scheel E Saido TC Schilling S Demuth H-U Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-betaBiochemistry (Mosc)2008 674057413

    Not in our library10.1021/bi800250p

  68. 68.

    Jawhar S Wirths O Schilling S Graubner S Demuth H-U Bayer TA Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate Aβ formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD miceJ Biol Chem2011 644544460

    Not in our library10.1074/jbc.m110.185819

  69. 69.

    Tekirian TL Yang AY Glabe C Geddes JW Toxicity of pyroglutaminated amyloid beta-peptides 3(pE)-40 and -42 is similar to that of Aβ1–40 and -42J Neurochem1999 615841589

    Not in our library10.1046/j.1471-4159.1999.0731584.x

  70. 70.

    Youssef I Florent-Béchard S Malaplate-Armand C Koziel V Bihain B Olivier J-L Leininger-Muller B Kriem B Oster T Pillot T N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosisNeurobiol Aging2008 613191333

    Not in our library10.1016/j.neurobiolaging.2007.03.005

  71. 71.

    He W Barrow CJ The Aβ3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length AβBiochemistry (Mosc)1999 61087110877

    Not in our library10.1021/bi990563r

  72. 72.

    Christensen DZ Kraus SL Flohr A Cotel M-C Wirths O Bayer TA Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI miceActa Neuropathol (Berl)2008 6647655

    Not in our library10.1007/s00401-008-0451-6

  73. 73.

    Kawarabayashi T Younkin LH Saido TC Shoji M Ashe KH Younkin SG Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer’s diseaseJ Neurosci2001 6372381

    Not in our library10.1523/jneurosci.21-02-00372.2001

  74. 74.

    Wirths O Breyhan H Cynis H Schilling S Demuth H-U Bayer TA Intraneuronal pyroglutamate-Aβ 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse modelActa Neuropathol (Berl)2009 6487496

    Not in our library10.1007/s00401-009-0557-5

  75. 75.

    Alexandru A Jagla W Graubner S Becker A Bäuscher C Kohlmann S Sedlmeier R Raber KA Cynis H Rönicke R Reymann KG Petrasch-Parwez E Hartlage-Rübsamen M Waniek A Rossner S Schilling S Osmand AP Demuth H-U von Hörsten S Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formationJ Neurosci Off J Soc Neurosci2011 61279012801

    Not in our library10.1523/jneurosci.1794-11.2011

  76. 76.

    Szendrei GI Fabian H Mantsch HH Lovas S Nyéki O Schön I Otvos L Jr Aspartate-bond isomerization affects the major conformations of synthetic peptidesEur J Biochem FEBS1994 6917924

    Not in our library10.1111/j.1432-1033.1994.t01-1-00917.x

  77. 77.

    Roher AE Lowenson JD Clarke S Wolkow C Wang R Cotter RJ Reardon IM Zürcher-Neely HA Heinrikson RL Ball MJ Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer’s diseaseJ Biol Chem1993 630723083

    Not in our library

  78. 78.

    Fabian H Szendrei GI Mantsch HH Greenberg BD Otvös L Jr Synthetic post-translationally modified human Aβ peptide exhibits a markedly increased tendency to form beta-pleated sheets in vitroEur J Biochem FEBS1994 6959964

    Not in our library10.1111/j.1432-1033.1994.tb18811.x

  79. 79.

    Shimizu T Fukuda H Murayama S Izumiyama N Shirasawa T Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer’s diseaseJ Neurosci Res2002 6451461

    Not in our library10.1002/jnr.10350

  80. 80.

    Fukuda H Shimizu T Nakajima M Mori H Shirasawa T Synthesis, aggregation, and neurotoxicity of the Alzheimer’s Aβ1-42 amyloid peptide and its isoaspartyl isomersBioorg Med Chem Lett1999 6953956

    Not in our library10.1016/s0960-894x(99)00121-3

  81. 81.

    Kuo YM Webster S Emmerling MR De Lima N Roher AE Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Aβ peptides of Alzheimer’s diseaseBiochim Biophys Acta1998 6291298

    Not in our library10.1016/s0925-4439(98)00014-3

  82. 82.

    Fonseca MI Head E Velazquez P Cotman CW Tenner AJ The presence of isoaspartic acid in β-amyloid plaques indicates plaque ageExp Neurol1999 6277288

    Not in our library10.1006/exnr.1999.7058

  83. 83.

    Iwatsubo T Saido TC Mann DM Lee VM Trojanowski JQ Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaquesAm J Pathol1996 618231830

    Not in our library

  84. 84.

    Kubo T Kumagae Y Miller CA Kaneko I Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: implications in the pathogenesis of Alzheimer diseaseJ Neuropathol Exp Neurol2003 6248259

    Not in our library10.1093/jnen/62.3.248

  85. 85.

    Tomiyama T Asano S Furiya Y Shirasawa T Endo N Mori H Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analoguesJ Biol Chem1994 61020510208

    Not in our library

  86. 86.

    Tambo K Yamaguchi T Kobayashi K Terauchi E Ichi I Kojo S Racemization of the aspartic acid residue of amyloid-β peptide by a radical reactionBiosci Biotechnol Biochem2013 6416418

    Not in our library10.1271/bbb.120797

  87. 87.

    Inoue K Hosaka D Mochiuki N Akatsu H Tsutsumiuchi K Hashizume Y Matsukawa N Yamamoto T Toyo’oka T Simultaneous determination of post-translational racemization and isomerization of N-terminal amyloid-beta in Alzheimer’s brain tissues by covalent chiral derivatized ultra-performance liquid chromatography tandem mass spectrometryAnal Chem2013 6797804

    Not in our library10.1021/ac403315h

  88. 88.

    Portelius E Gustavsson MK Zetterberg H Andreasson U Blennow K Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer’s disease: from the cell to the patientNeurodegener Dis2012 6138140

    Not in our library10.1159/000334537

  89. 89.

    Welge V Fiege O Lewczuk P Mollenhauer B Esselmann H Klafki H-W Wolf S Trenkwalder C Otto M Kornhuber J Wiltfang J Bibl M Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer’s diseaseJ Neural Transm Vienna Austria 19962009 6203212

    Not in our library10.1007/s00702-008-0177-6

  90. 90.

    Bibl M Mollenhauer B Lewczuk P Esselmann H Wolf S Otto M Kornhuber J Rüther E Wiltfang J Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasiasDement Geriatr Cogn Disord2011 63744

    Not in our library10.1159/000322370

  91. 91.

    Britschgi M Olin CE Johns HT Takeda-Uchimura Y LeMieux MC Rufibach K Rajadas J Zhang H Tomooka B Robinson WH Clark CM Fagan AM Galasko DR Holtzman DM Jutel M Kaye JA Lemere CA Leszek J Li G Peskind ER Quinn JF Yesavage JA Ghiso JA Wyss-Coray T Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s diseaseProc Natl Acad Sci USA2009 61214512150

    Not in our library10.1073/pnas.0904866106

  92. 92.

    Marcello A Wirths O Schneider-Axmann T Degerman-Gunnarsson M Lannfelt L Bayer TA Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer’s diseaseNeurobiol Aging2011 613791387

    Not in our library10.1016/j.neurobiolaging.2009.08.011

  93. 93.

    Sullivan CP Berg EA Elliott-Bryant R Fishman JB McKee AC Morin PJ Shia MA Fine RE Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer’s disease cerebral cortex with pyroglutamate-Aβ 11 forming the central coreNeurosci Lett2011 6109112

    Not in our library10.1016/j.neulet.2011.09.071

Cited by papers we hold 6

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.